Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIRECTION: Discontinuation Versus Continuation of Riociguat Monotherapy in CTEPH
NCT07644377Phase 3Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2026
- Primary completion
- Jan 2031
- Countries
- 1
01
Overview
A Phase 3 trial of riociguat in chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
riociguat
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NCT07644377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07644377.